Search

Your search keyword '"Tischkowitz, M"' showing total 682 results

Search Constraints

Start Over You searched for: Author "Tischkowitz, M" Remove constraint Author: "Tischkowitz, M"
682 results on '"Tischkowitz, M"'

Search Results

1. Classification of variants of reduced penetrance in high-penetrance cancer susceptibility genes: Framework for genetics clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group-UK)

4. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

5. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.

6. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

7. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

8. Exploring the barriers to and facilitators of implementing CanRisk in primary care: a qualitative thematic framework analysis

9. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium

10. Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome.

11. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.

12. Proactive breast cancer risk assessment in primary care: a review based on the principles of screening.

13. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

14. Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer.

15. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.

17. Second primary cancer risks for female and male breast cancer survivors in England

18. Incorporating alternative Polygenic Risk Scores into the BOADICEA breast cancer risk prediction model

19. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.

20. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors

21. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

22. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

23. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

24. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

25. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

26. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence

27. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome

28. A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

30. Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes

31. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

34. Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population

36. GENOTYPE-PHENOTYPE ASSOCIATIONS PROVIDE A RATIONAL TO IDENTIFY POTENTIALLY ACTIONABLE VUS

37. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

38. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe

39. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

40. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

41. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

42. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

43. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

44. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

45. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

46. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

47. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

48. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

49. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

50. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

Catalog

Books, media, physical & digital resources